Drug resistance in brain diseases and the role of drug efflux transporters

By Wolfgang Löscher, Heidrun Potschka. Nature Reviews Neuroscience, 2005

908 citations recorded by the source corpus.

Subfields: Oncology, Pediatrics, Perinatology and Child Health, Physiology

View Paper: https://www.semanticscholar.org/paper/a21b09fff1b9af4c2b28efbdef64cd6e57eb24af

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. F. Sharom
2. Wolfgang Löscher
3. Sanjay M. Sisodiya
4. Heidrun Potschka
5. A. Vezzani

In Pediatrics, Perinatology and Child Health

1. F. Sharom
2. Wolfgang Löscher
3. A. Vezzani
4. Heidrun Potschka

In Physiology

1. F. Sharom
2. Wolfgang Löscher

Citations in the corpus

• Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME (2013, neutral): “1996) and several antiepileptic drugs (Dombrowski et al. 2001; Potschka et al. 2003a, b; Loscher and Potschka 2005).”
• Blood–brain Barrier: Structural Components and Function Under Physiologic and Pathologic Conditions (2006, background): “Drug efflux transporters, such as P-glycoprotein (Pgp), are mainly present on the luminal membrane surface (Loscher and Potschka 2005b).”
• The blood-brain barrier in brain homeostasis and neurological diseases. (2009, neutral): “anti-HIV drugs [71,220,221].”
• The blood-brain barrier in Alzheimer's disease (2017, neutral): “…and/or abluminal surfaces regulate the transport of macromolecules and proteins in and out of the brain (Löscher and Potschka, 2005; Saunders et al., 2013; Xiao and Gan, 2013); and (3) generally, the BMECs serve as an interface for communication between…”
• The blood-brain barrier in health and chronic neurodegenerative disorders. (2008, neutral): “The multidrug resistance transporter P-glycoportein (P-gp) is an ATP-dependent efflux pump which mediates rapid removal of ingested toxic lipophilic metabolites, such as many amphipatic cationic drugs (Loscher and Potschka, 2005; Hermann and Bassetti, 2007).”
• ABC multidrug transporters: structure, function and role in chemoresistance. (2008, background): “The presence of efflux pumps in the endothelial cells of the brain capillaries also has a far-reaching impact on pharmacotherapy of brain diseases, including cancer, AIDS, Parkinson’s disease, epilepsy and schizophrenia [74,75].”
• Drug Resistance in Epilepsy: Clinical Impact, Potential Mechanisms, and New Innovative Treatment Options (2020, background): “The “transporter hypothesis” suggests resistance is due to inadequate penetration of ASDs across the BBB because of increased expression of multidrug efflux transporters (Löscher and Potschka, 2005; Tang et al., 2017).”
• Critical review of current animal models of seizures and epilepsy used in the discovery and development of new antiepileptic drugs. (2011, background): “Interestingly, the only common finding in both models was increased expression of the efflux (‘‘multidrug’’) transporter P-glycoprotein in brain capillary endothelial cells that form the blood–brain barrier, which has also been described in epileptogenic brain tissue of patients undergoing resective”